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Dear Editor, 
Choroid plexus carcinoma (CPC) is a WHO grade III intraventricular neoplasm that represents 15–20 % of 
all choroid plexus tumors. Since it mainly occurs in children (representing about 80 % of all CPC), the 
knowledge of the disease in adult is limited. Surgical resection is a well-established treatment option at 
diagnosis; however, there are neither a standard adjuvant treatments nor well-defined therapies at 
progression. Neoplastic meningitis (NM) is an uncommon pattern of recurrence with dismal prognosis, 
even despite combination of systemic and intrathecal chemotherapy 1, 2. 
Case report 
In June 2003, a 50-year-old male developed dizziness and progressive gait disturbance. MRI showed an 
enhancing tumor in the fourth ventricle without any meningeal involvement. After a total surgical 
resection, the histological examination revealed a CPC (Fig. 1a). MGMT (O6-methylguanine-DNA 
methyltransferase) promoter was retrospectively analyzed and resulted unmethylated. The patient 
received adjuvant-involved field radiotherapy (RT) (DFT 42 Gy/21 fractions): the MRI after RT did not 
show any residual tumor and patient obtained a significant improvement of ataxia lasting until the end of 
2010. In January 2011, he developed gait disturbance, loss of strength and radicular pain at L5–S1 on the 
right side. Spine MRI showed multiple leptomeningeal contrast enhancing lesions (Fig. 2). The patient 
underwent a C1–C3 laminectomy that confirmed the original histological diagnosis and a lumbar 
puncture demonstrated malignant cells in the CSF (Fig. 1b). Because of the progressive neurological 
worsening, the CSF involvement and the presence of a D12–L1 and S1 bulky disease, we treated the 
patient with an involved-field RT (20 Gy/5 fr) on the bulky disease, followed by 9 cycles of intrathecal 
ARA-C and 12 cycles of systemic chemotherapy with temozolomide (TMZ) without overlapping toxicities. 
One month after the start of chemotherapy the patient showed a gradual pain relief, an improvement of 
the strength of the right side and the Karnofsky performance status progressively improved over time 
from 50 to 90. CSF cytology became negative while the MRI findings were unchanged. After 12 months of 
treatment a CSF relapse occurred, but neurological status and neuroimaging findings remained 
unchanged. In March 2012, TMZ and intrathecal ARA-C were interrupted because of initial signs of 
hepatotoxicity, however, in July 2014 the patient is still alive. 
 
Fig. 1  
a Permanent section showing high cellularity, nuclear atypia, poorly structured papillary pattern and an 
increased mitotic rate, all criteria diagnostic for choroid plexus carcinoma (H&E, original magnification 
×20, ×20 and ×40, respectively). b CSF cytology at diagnosis of the neoplastic meningitis: presence of 
choroid plexus carcinoma cells (one of these in mitotic phase) with prominent nucleoli, chromatin 
aggregates and large eosinophilic cytoplasm 
 
Fig. 2  
Multiple nodular and linear enhancing lesions on MRI in the leptomeninges of cervical and dorsal spinal 
cord at diagnosis 
Surgical resection represents the mainstay of therapy for CPC: it can allow an immediate clinical 
improvement and extent of surgical resection is the most important predictor of PFS. The role of adjuvant 
RT is still controversial. Several studies report an improvement of the OS and PFS after total and subtotal 
surgical resection alone. Conversely, some authors suggest craniospinal RT (CSRT) to avoid or delay an 
early CSF spread 3; however, as CSRT is associated with a significant risk of neurotoxicity, conformal RT 
has been proposed as an alternative. A retrospective study comparing the efficacy of adjuvant CSRT 
versus involved-field RT showed a significant benefit both in terms of PFS and OS for patients treated 
with CSRT 4. In our case we chose conformal RT after initial surgery because surgical resection was 
complete and there was no evidence of dissemination. 
When a leptomeningeal spread occurs at tumor progression, involved-field RT on bulky disease has been 
proposed to obtain a quick palliation of symptoms, remove the blockage of CSF circulation and allow a 
safe administration of intrathecal chemotherapy. Many different antineoplastic drugs have been 
employed without a clear advantage of one over the other 5. A meta-analysis has compared response and 
survival among patients who received different schedules drugs: the most effective antineoplastic agent 
appeared to be etoposide 6. The role of other antineoplastic drugs in addition to etoposide is being 
investigated. Two choroid plexus papillomas with diffuse NM were treated with TMZ without appreciable 
changes in the size or distribution of lesions, but both patients had a neurological improvement. 
Methylation of the MGMT gene promoter, a predictive marker for response to chemotherapy with 
alkylating agents in glioblastoma, has been found in 58 % of 36 choroid plexus tumors 7, but correlations 
with TMZ efficacy were not investigated. In one reported-CPC patient with unmethylated MGMT 
promoter, adjuvant TMZ did not provide any benefit in terms of disease control 8 suggesting that the 
unmethylated status could predict the lack of response. 
Intrathecal ARA-C is approved for the treatment of CNS involvement from hematological malignancies 
and its use in NM due to primary brain tumors has been reported in few studies only; however, in these 
series, CPCs have not been included. Up to date only one disseminated CPP was treated with intrathecal 
ARA-C associated with systemic bleomycin, cysplatinum and etoposide with poor result in term of OS 2. 
To best of our knowledge, this is the first report of NM from a CPC with long-lasting neurological and CSF 
response (11 years) and prolonged survival (>3 years) following a combination of radiotherapy, 
temozolomide and liposomal cytarabine.  
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